Related Experiment Video
Updated: May 11, 2026
14:14
Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications
Published on: February 28, 2014
Circulating tumor cells in breast cancer
Malgorzata Banys1, Volkmar Müller, Carola Melcher
1Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen, Germany. maggybanys@yahoo.de
Summary
Detecting circulating tumor cells (CTCs) in blood offers a less invasive alternative to bone marrow biopsies for assessing disseminated tumor cells (DTCs) in breast cancer patients. CTC detection shows promise for prognosis and therapy monitoring.
Area of Science:
- Oncology
- Translational Cancer Research
Background:
- Disseminated tumor cells (DTCs) are found in 30-40% of primary breast cancer patients.
- DTC presence correlates strongly with poor clinical outcomes.
- Bone marrow biopsy, a method for DTC detection, is invasive.
Purpose of the Study:
- To explore circulating tumor cells (CTCs) as a less invasive alternative to bone marrow biopsy for DTC detection.
- To evaluate the prognostic value of CTC detection in primary and metastatic cancer.
- To assess the utility of CTC evaluation for therapy monitoring and identifying new therapeutic targets.
Main Methods:
- Analysis of circulating tumor cells (CTCs) in blood samples.
- Comparison with bone marrow biopsy for disseminated tumor cell (DTC) detection.
- Review of clinical trial data on CTC detection and prognostic significance.
Main Results:
- Circulating tumor cell (CTC) detection is a promising prognostic tool in various cancer settings.
- CTC evaluation may aid in monitoring treatment efficacy.
- Characterization of CTCs can help identify novel therapeutic targets for metastasis.
Conclusions:
- CTC detection in blood is a viable and less invasive alternative to bone marrow biopsies for assessing tumor cell dissemination.
- CTC analysis holds significant potential for improving cancer patient prognosis and guiding therapeutic strategies.
- Further research into CTCs could lead to new treatments targeting the metastatic cascade.
Related Concept Videos
02:30Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:40Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...